The USPSTF recommends tamoxifen, raloxifene, or aromatase inhibitors for women at high breast cancer risk.
The USPSTF recommends tamoxifen, raloxifene, or aromatase inhibitors for women at high breast cancer risk. However, women who are at low risk for breast cancer may be harmed by these drugs and should not take them, says the United States Preventive Services Task Force (USPSTF). This new recommendation updates the USPSTF's 2013 guidelines, and aromatase inhibitors are included for the first time. The new advice applies to asymptomatic women 35 years and older with previous benign breast lesions. However, it does not cover women currently or previously diagnosed with breast cancer or ductal carcinoma in situ. Only 10% to 30% of primary care providers currently prescribe risk-reducing drugs to prevent breast cancer, which is the most common nonskin cancer and second leading cause of cancer death in women. In 2018, new cases of breast cancer accounted for 30% of all new cancer cases in women. To read the recommendation, go to https://jamanetwork.com/journals/jama/fullarticle/2749221.Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.